C4 Therapeutics Stock Probability of Future Stock Price Finishing Under 6.05
| CCCC Stock | USD 6.06 0.02 0.33% |
CCCC |
C4 Therapeutics Target Price Odds to finish below 6.05
The tendency of CCCC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 6.05 or more in 90 days |
| 6.06 | 90 days | 6.05 | about 54.44 |
Based on a normal probability distribution, the odds of C4 Therapeutics to drop to $ 6.05 or more in 90 days from now is about 54.44 (This C4 Therapeutics probability density function shows the probability of CCCC Stock to fall within a particular range of prices over 90 days) . Probability of C4 Therapeutics price to stay between $ 6.05 and its current price of $6.06 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.16 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, C4 Therapeutics will likely underperform. Additionally C4 Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. C4 Therapeutics Price Density |
| Price |
Predictive Modules for C4 Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as C4 Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of C4 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
C4 Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. C4 Therapeutics is not an exception. The market had few large corrections towards the C4 Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold C4 Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of C4 Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.0063 | |
β | Beta against Dow Jones | 1.16 | |
σ | Overall volatility | 0.43 | |
Ir | Information ratio | 0 |
C4 Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of C4 Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for C4 Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| C4 Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 20.76 M. Net Loss for the year was (132.49 M) with loss before overhead, payroll, taxes, and interest of (86.75 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial |
C4 Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CCCC Stock often depends not only on the future outlook of the current and potential C4 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. C4 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 49.6 M | |
| Cash And Short Term Investments | 253.7 M |
C4 Therapeutics Technical Analysis
C4 Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. CCCC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of C4 Therapeutics. In general, you should focus on analyzing CCCC Stock price patterns and their correlations with different microeconomic environments and drivers.
C4 Therapeutics Predictive Forecast Models
C4 Therapeutics' time-series forecasting models is one of many C4 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary C4 Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about C4 Therapeutics
Checking the ongoing alerts about C4 Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for C4 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| C4 Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 20.76 M. Net Loss for the year was (132.49 M) with loss before overhead, payroll, taxes, and interest of (86.75 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial |
Check out C4 Therapeutics Backtesting, C4 Therapeutics Valuation, C4 Therapeutics Correlation, C4 Therapeutics Hype Analysis, C4 Therapeutics Volatility, C4 Therapeutics History as well as C4 Therapeutics Performance. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.